Author

Peter Quehenberger

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE
SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE

Peter Quehenberger  et al.

SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Peter Quehenberger  et al.

VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE
VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE

Peter Quehenberger  et al.

FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Peter Quehenberger  et al.

CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Peter Quehenberger  et al.

Item 1 - 5 / 5
1